GILEAD SCIENCES INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
GILEAD SCIENCES INC. - More news...
GILEAD SCIENCES INC. - More news...
- Asian American Women Engineers Find Community and Purpose at Gilead
- Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
- Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story
- AbTherx Announces License Agreement with Gilead
- Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
- Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
- Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
- Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
- Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer
- CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
- Gilead Sciences to Present at Upcoming Investor Conference
- How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story
- Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
- Gilead Appoints Cindy Perettie Executive Vice President of Kite
- Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
- Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
- Gilead Emphasizes Unique Ways To Hire Top Talent
- Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
- CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
- Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
- Gilead Sciences to Present at Upcoming Investor Conferences
- GILEAD SCIENCES ANNOUNCES LAUNCH OF ASIA PACIFIC RAINBOW GRANT 2023
- Gilead Sciences Announces First Quarter 2023 Financial Results
- Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
- Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
- Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
- Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
- Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma